CHICAGO--Mylan is working to bring a biosimilar of Roche’s Herceptin to the U.S. market--and now, it has some data in hand that could help it do just that.
Mylan’s contender--MYL-14010--is comparable to Herceptin at treating advanced, HER-2 positive breast cancer when it comes to both efficacy and safety, according to results from a Phase III study that rolled out Friday at the American Society of Clinical Oncology’s annual meeting here.
In the trial, 69.6% of patients taking Mylan's copycat med experienced tumor shrinkage, with 64% responding to Herceptin. And 38% of patients on the Mylan drug experienced serious side effects, compared with 36% of those taking Herceptin.
It’s good news for Mylan, which is looking to break into the tiny club of drugmakers with FDA-approved biosims. While Mylan and partner Biocon have boasted Indian approval for their product since late 2013--in part thanks to a decision from Roche to quit trying to protect its patent--in the U.S., it’s only Novartis’ Sandoz and a team of Korea’s Celltrion and Pfizer’s Hospira that currently have regulatory green lights.
If all goes as planned for the generics powerhouse, it’ll get a shot at the $6.54 billion in sales Herceptin raked in for Roche last year. And meanwhile, the Swiss pharma giant has a pair of new products on its hands that it hopes can close the revenue gap: Tecentriq, a recently approved immuno-oncology standout, and ocrelizumab, a near-market candidate that’s poised to shake up the multiple sclerosis landscape once it gets an FDA go-ahead.
- read the release
Roche's Tecentriq bursts onto immuno-oncology scene, with Merck and BMS in its sights
Roche looks ahead to immuno-oncology, MS to back up big-selling cancer meds
Biocon, Mylan plan appeals of Delhi court ruling on biosimilar
Mylan, Biocon ready to roll out Herceptin biosimilar in India